Wrexham striker Ollie Palmer has scored two goals in the space of a minute in stoppage time then converted one of the team’s ...

Analysts have given Stoke Therapeutics a total of 3 ratings, with the consensus rating being Buy. The average one-year price target is $29.0, indicating a potential 121.37% upside.

Wrexham have taken a significant step toward boosting their stadium’s capacity, having officially submitted a planning application to Wrexham City Borough Council. The club aims to add an extra 2,250 ...

The market expects Stoke Therapeutics, Inc. (STOK) to deliver a year-over-year decline in earnings on higher revenues when it ...

The club aims to add an extra 2,250 seats to the under-construction Kop Stand at the SToK Cae Ras, in a move designed to elevate the venue to international hosting standards.

Here are some of the largest recent moves: FMR LLC added 2,376,741 shares (+1438.7%) to their portfolio in Q1 2025, for an estimated $15,805,327 MARSHALL WACE, LLP added 1,180,351 shares (+124.1% ...

Find the latest analyst research, reports, and ratings for Stoke Therapeutics, Inc. Common Stock (STOK) at Nasdaq.com.

The market expects Stoke Therapeutics, Inc. (STOK) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2025.